Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments - Segment Information (Details)

v3.22.2.2
Note 14 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax $ 6,519   $ 13,063   $ 6,519 $ 35,549  
Grant and other revenue 51,007   247,983   51,007 349,234  
Revenues, Total 57,526   261,046   57,526 384,783  
Cost of revenue, excluding depreciation and amortization 473   0   473 0  
Research and development expenses 1,723,988   1,498,056   2,893,242 2,720,810  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,233,895   1,412,752   3,021,046 3,625,749  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 21,771   19,858   44,649 37,606  
Loss from operations [3] (2,922,601)   (2,669,620)   (5,901,884) (5,999,382)  
Other expense (4) (76,858) [4]   (4,420) [4]   (84,819) [4] 358,450 [5]  
Net loss (2,999,459) $ (2,987,245) (2,674,040) $ (2,966,892) (5,986,703) (5,640,932)  
Total assets, net of depreciation and amortization 2,503,705       2,503,705   $ 6,644,833
Capital expenditures 48,657   2,707   48,657 2,707  
UNITED STATES              
Total assets, net of depreciation and amortization 2,093,815   11,080,979   2,093,815 11,080,979  
Non-US [Member]              
Total assets, net of depreciation and amortization 409,890   200,331   409,890 200,331  
Diagnostics Segment [Member]              
Grant and other revenue 51,007   247,983   51,007 349,234  
Revenues, Total 57,526   261,046   57,526 384,783  
Cost of revenue, excluding depreciation and amortization 473       473    
Research and development expenses 1,636,691   1,358,123   2,626,578 2,452,513  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 0   0   0 0  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 6,041   6,041   12,081 12,081  
Loss from operations [3] (1,585,679)   (1,103,118)   (2,581,606) (2,079,811)  
Other expense (4) 0 [4]   0 [4]   0 [4] 0 [5]  
Net loss (1,585,679)   (1,103,118)   (2,581,606) (2,079,811)  
Capital expenditures 40,221   0   40,221 0  
Diagnostics Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 50,000   269,464   50,000 269,464  
Diagnostics Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization 384,294   199,741   384,294 199,741  
Therapeutics Segment [Member]              
Grant and other revenue 0   0   0 0  
Revenues, Total 0   0   0 0  
Cost of revenue, excluding depreciation and amortization 0       0    
Research and development expenses 87,297   139,933   266,664 268,297  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 3,001   873   3,001 2,879  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 0   0   0 0  
Loss from operations [3] (90,298)   (140,806)   (269,665) (271,176)  
Other expense (4) 0 [4]   0 [4]   0 [4] 0 [5]  
Net loss (90,298)   (140,806)   (269,665) (271,176)  
Capital expenditures 0   0   0 0  
Therapeutics Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 0   0   0 0  
Therapeutics Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization 0   0   0 0  
Corporate Segment [Member]              
Grant and other revenue 0   0   0 0  
Revenues, Total 0   0   0 0  
Cost of revenue, excluding depreciation and amortization 0       0    
Research and development expenses 0   0   0 0  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,230,894   1,411,879   3,018,045 3,622,870  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 15,730   13,817   32,568 25,525  
Loss from operations [3] (1,246,624)   (1,425,696)   (3,050,613) (3,648,395)  
Other expense (4) (76,858) [4]   (4,420) [4]   (84,819) [4] 358,450 [5]  
Net loss (1,323,482)   (1,430,116)   (3,135,432) (3,289,945)  
Capital expenditures 8,436   2,707   8,436 2,707  
Corporate Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 2,043,815   10,811,515   2,043,815 10,811,515  
Corporate Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization 25,596   590   25,596 590  
License [Member]              
Revenue from Contract with Customer, Including Assessed Tax 0   13,063   0 35,549  
License [Member] | Diagnostics Segment [Member]              
Revenue from Contract with Customer, Including Assessed Tax     13,063     35,549  
License [Member] | Therapeutics Segment [Member]              
Revenue from Contract with Customer, Including Assessed Tax     0     0  
License [Member] | Corporate Segment [Member]              
Revenue from Contract with Customer, Including Assessed Tax     0     0  
Sales Revenue [Member]              
Revenue from Contract with Customer, Including Assessed Tax 6,519   $ 0   6,519 $ 0  
Sales Revenue [Member] | UNITED STATES              
Revenue from Contract with Customer, Including Assessed Tax 0       0    
Sales Revenue [Member] | Non-US [Member]              
Revenue from Contract with Customer, Including Assessed Tax 6,519       6,519    
Sales Revenue [Member] | Diagnostics Segment [Member] | UNITED STATES              
Revenue from Contract with Customer, Including Assessed Tax 0       0    
Sales Revenue [Member] | Diagnostics Segment [Member] | Non-US [Member]              
Revenue from Contract with Customer, Including Assessed Tax 6,519       6,519    
Sales Revenue [Member] | Therapeutics Segment [Member] | UNITED STATES              
Revenue from Contract with Customer, Including Assessed Tax 0       0    
Sales Revenue [Member] | Therapeutics Segment [Member] | Non-US [Member]              
Revenue from Contract with Customer, Including Assessed Tax 0       0    
Sales Revenue [Member] | Corporate Segment [Member] | UNITED STATES              
Revenue from Contract with Customer, Including Assessed Tax 0       0    
Sales Revenue [Member] | Corporate Segment [Member] | Non-US [Member]              
Revenue from Contract with Customer, Including Assessed Tax $ 0       $ 0    
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($21,771 and $19,858 for the three-month periods ended June 30, 2022 and 2021, and $44,649 and $37,606 for the six-month periods ended June 30, 2022 and 2021, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.
[5] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.